


New Medicare benefit would limit insulin copays to \$35 a month

May 27 2020



Reacting to skyrocketing prices for insulin, the Trump Administration

announced on Tuesday a new benefit that would limit Medicare recipients' copays for insulin to a maximum of \$35 a month and save them about \$446 a year if they have prescription plans that offer the benefit.

Instead of the fluctuating copay amounts that are common now, there would be a manageable amount, the *Associated Press* reported. The insulin benefit will be voluntary, so Medicare recipients who want to take advantage of it must pick an insurance plan that provides it. Most will have access to such plans during open enrollment this fall.

The benefit was announced Tuesday by the Trump administration, which brokered a deal between insulin manufacturers and major insurers, Medicare chief Seema Verma told the *AP*. The three major insulin suppliers, Eli Lilly, Novo Nordisk, and Sanofi, were all involved.

Verma said 1,750 insurance plans that offer drug coverage to Medicare recipients have agreed to limit copays, which is expected to lead to a small increase in premiums, the *AP* reported. The benefit would cover a number of [insulin](#) products, including pen and vial forms for rapid-acting, short-acting, intermediate-acting, and long-acting versions.

More information: [AP News Article](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: New Medicare benefit would limit insulin copays to \$35 a month (2020, May 27) retrieved 27 April 2024 from <https://medicalxpress.com/news/2020-05-medicare-benefit-limit-insulin-copays.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--